These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 26037932)

  • 1. Zanamivir Amidoxime- and N-Hydroxyguanidine-Based Prodrug Approaches to Tackle Poor Oral Bioavailability.
    Schade D; Kotthaus J; Riebling L; Kotthaus J; Müller-Fielitz H; Raasch W; Hoffmann A; Schmidtke M; Clement B
    J Pharm Sci; 2015 Sep; 104(9):3208-19. PubMed ID: 26037932
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of novel potent orally bioavailable oseltamivir derivatives active against resistant influenza A.
    Schade D; Kotthaus J; Riebling L; Kotthaus J; Müller-Fielitz H; Raasch W; Koch O; Seidel N; Schmidtke M; Clement B
    J Med Chem; 2014 Feb; 57(3):759-69. PubMed ID: 24422530
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro neuraminidase inhibitory activity of four neuraminidase inhibitors against clinical isolates of influenza virus in the Japanese 2012-2013 season.
    Ikematsu H; Kawai N; Iwaki N; Kashiwagi S
    J Infect Chemother; 2015 Jan; 21(1):39-42. PubMed ID: 25277670
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis of C-4-modified zanamivir analogs as neuraminidase inhibitors and their anti-AIV activities.
    Ye D; Shin WJ; Li N; Tang W; Feng E; Li J; He PL; Zuo JP; Kim H; Nam KY; Zhu W; Seong BL; No KT; Jiang H; Liu H
    Eur J Med Chem; 2012 Aug; 54():764-70. PubMed ID: 22795831
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Zanamivir-resistant influenza viruses with Q136K or Q136R neuraminidase residue mutations can arise during MDCK cell culture creating challenges for antiviral susceptibility monitoring.
    Little K; Leang SK; Butler J; Baas C; Harrower B; Mosse J; Barr IG; Hurt AC
    Euro Surveill; 2015; 20(45):. PubMed ID: 26608955
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neuraminidase inhibitor susceptibility profile of pandemic and seasonal influenza viruses during the 2009-2010 and 2010-2011 influenza seasons in Japan.
    Dapat C; Kondo H; Dapat IC; Baranovich T; Suzuki Y; Shobugawa Y; Saito K; Saito R; Suzuki H
    Antiviral Res; 2013 Sep; 99(3):261-9. PubMed ID: 23791870
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A zanamivir dimer with prophylactic and enhanced therapeutic activity against influenza viruses.
    Tarbet EB; Hamilton S; Vollmer AH; Luttick A; Ng WC; Pryor M; Hurst BL; Crawford S; Smee DF; Tucker SP
    J Antimicrob Chemother; 2014 Aug; 69(8):2164-74. PubMed ID: 24777908
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sensitivity of influenza viruses to zanamivir and oseltamivir: a study performed on viruses circulating in France prior to the introduction of neuraminidase inhibitors in clinical practice.
    Ferraris O; Kessler N; Lina B
    Antiviral Res; 2005 Oct; 68(1):43-8. PubMed ID: 16125799
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of GS 4104 as an orally bioavailable prodrug of the influenza virus neuraminidase inhibitor GS 4071.
    Li W; Escarpe PA; Eisenberg EJ; Cundy KC; Sweet C; Jakeman KJ; Merson J; Lew W; Williams M; Zhang L; Kim CU; Bischofberger N; Chen MS; Mendel DB
    Antimicrob Agents Chemother; 1998 Mar; 42(3):647-53. PubMed ID: 9517946
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis of acylguanidine zanamivir derivatives as neuraminidase inhibitors and the evaluation of their bio-activities.
    Lin CH; Chang TC; Das A; Fang MY; Hung HC; Hsu KC; Yang JM; von Itzstein M; Mong KK; Hsu TA; Lin CC
    Org Biomol Chem; 2013 Jun; 11(24):3943-8. PubMed ID: 23695381
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiviral activity of baicalin against influenza A (H1N1/H3N2) virus in cell culture and in mice and its inhibition of neuraminidase.
    Ding Y; Dou J; Teng Z; Yu J; Wang T; Lu N; Wang H; Zhou C
    Arch Virol; 2014 Dec; 159(12):3269-78. PubMed ID: 25078390
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro neuraminidase inhibitory activity of four neuraminidase inhibitors against influenza virus isolates in the 2011-2012 season in Japan.
    Ikematsu H; Kawai N; Iwaki N; Kashiwagi S
    J Infect Chemother; 2014 Feb; 20(2):77-80. PubMed ID: 24560563
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In Vitro Combinations of Baloxavir Acid and Other Inhibitors against Seasonal Influenza A Viruses.
    Checkmahomed L; Padey B; Pizzorno A; Terrier O; Rosa-Calatrava M; Abed Y; Baz M; Boivin G
    Viruses; 2020 Oct; 12(10):. PubMed ID: 33049959
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oral administration of a prodrug of the influenza virus neuraminidase inhibitor GS 4071 protects mice and ferrets against influenza infection.
    Mendel DB; Tai CY; Escarpe PA; Li W; Sidwell RW; Huffman JH; Sweet C; Jakeman KJ; Merson J; Lacy SA; Lew W; Williams MA; Zhang L; Chen MS; Bischofberger N; Kim CU
    Antimicrob Agents Chemother; 1998 Mar; 42(3):640-6. PubMed ID: 9517945
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Different neuraminidase inhibitor susceptibilities of human H1N1, H1N2, and H3N2 influenza A viruses isolated in Germany from 2001 to 2005/2006.
    Bauer K; Richter M; Wutzler P; Schmidtke M
    Antiviral Res; 2009 Apr; 82(1):34-41. PubMed ID: 19428593
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Laninamivir octanoate: a new long-acting neuraminidase inhibitor for the treatment of influenza.
    Ikematsu H; Kawai N
    Expert Rev Anti Infect Ther; 2011 Oct; 9(10):851-7. PubMed ID: 21973296
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comprehensive assessment of 2009 pandemic influenza A (H1N1) virus drug susceptibility in vitro.
    Gubareva LV; Trujillo AA; Okomo-Adhiambo M; Mishin VP; Deyde VM; Sleeman K; Nguyen HT; Sheu TG; Garten RJ; Shaw MW; Fry AM; Klimov AI
    Antivir Ther; 2010; 15(8):1151-9. PubMed ID: 21149922
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessing the oral bioavailability of difluorosialic acid prodrugs, potent viral neuraminidase inhibitors, using a snapshot PK screening assay.
    Arns S; Tan J; Sun S; Galey A; Zisman N; Ross F; Udechukwu J; Dercho S; Gusti V; Paquette J; Webb M; Bourque E; Withers SG; Liggins R
    Bioorg Med Chem Lett; 2015 Jun; 25(12):2505-9. PubMed ID: 25980910
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recent advances in neuraminidase inhibitor development as anti-influenza drugs.
    Feng E; Ye D; Li J; Zhang D; Wang J; Zhao F; Hilgenfeld R; Zheng M; Jiang H; Liu H
    ChemMedChem; 2012 Sep; 7(9):1527-36. PubMed ID: 22807317
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dihydropyrancarboxamides related to zanamivir: a new series of inhibitors of influenza virus sialidases. 1. Discovery, synthesis, biological activity, and structure-activity relationships of 4-guanidino- and 4-amino-4H-pyran-6-carboxamides.
    Smith PW; Sollis SL; Howes PD; Cherry PC; Starkey ID; Cobley KN; Weston H; Scicinski J; Merritt A; Whittington A; Wyatt P; Taylor N; Green D; Bethell R; Madar S; Fenton RJ; Morley PJ; Pateman T; Beresford A
    J Med Chem; 1998 Mar; 41(6):787-97. PubMed ID: 9526555
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.